IL233882B - Antagonists of bcl-2 and uses thereof in induction of apoptosis - Google Patents

Antagonists of bcl-2 and uses thereof in induction of apoptosis

Info

Publication number
IL233882B
IL233882B IL233882A IL23388214A IL233882B IL 233882 B IL233882 B IL 233882B IL 233882 A IL233882 A IL 233882A IL 23388214 A IL23388214 A IL 23388214A IL 233882 B IL233882 B IL 233882B
Authority
IL
Israel
Prior art keywords
bcl
apoptosis
antagonists
induction
Prior art date
Application number
IL233882A
Other languages
Hebrew (he)
Other versions
IL233882A0 (en
Original Assignee
Carmel Haifa Univ Economic Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2013/050138 external-priority patent/WO2013121428A1/en
Application filed by Carmel Haifa Univ Economic Corp Ltd filed Critical Carmel Haifa Univ Economic Corp Ltd
Priority to IL233882A priority Critical patent/IL233882B/en
Publication of IL233882A0 publication Critical patent/IL233882A0/en
Publication of IL233882B publication Critical patent/IL233882B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
IL233882A 2012-02-15 2014-07-30 Antagonists of bcl-2 and uses thereof in induction of apoptosis IL233882B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL233882A IL233882B (en) 2012-02-15 2014-07-30 Antagonists of bcl-2 and uses thereof in induction of apoptosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261598953P 2012-02-15 2012-02-15
PCT/IL2013/050138 WO2013121428A1 (en) 2012-02-15 2013-02-14 ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS
IL233882A IL233882B (en) 2012-02-15 2014-07-30 Antagonists of bcl-2 and uses thereof in induction of apoptosis

Publications (2)

Publication Number Publication Date
IL233882A0 IL233882A0 (en) 2014-09-30
IL233882B true IL233882B (en) 2021-08-31

Family

ID=51691309

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233882A IL233882B (en) 2012-02-15 2014-07-30 Antagonists of bcl-2 and uses thereof in induction of apoptosis

Country Status (1)

Country Link
IL (1) IL233882B (en)

Also Published As

Publication number Publication date
IL233882A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
IL254569B (en) St2l antagonists and methods of use
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1203493A1 (en) Substituted azabicycles and use thereof
EP2912178A4 (en) Super-enhancers and methods of use thereof
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
IL239369A0 (en) Pirocyclic morphinans and their use
SG11201408545RA (en) Polymer particles and use thereof
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
IL233875A (en) Composition and use thereof in the treatment of anal rhagades
EP2814839A4 (en) ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS
LT2845598T (en) Preparation for use in the prophylaxis and treatment of atypical osteoporosis
HK1201050A1 (en) Polypeptides and their use
EP2906576A4 (en) Glycosphingolipids and methods of use thereof
PL2858655T3 (en) Thyme extracts and their use
HK1210079A1 (en) Biglycan variant polypeptides and methods of use
EP2910485A4 (en) Container capable of being connected both vertically and horizontally
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
IL233882A0 (en) Antagonists of bcl-2 and uses thereof in induction of apoptosis
EP2924046A4 (en) Novel complex and use of same